The9 Limited said on August 11, 2026 that its Singapore investee Nanyang Biologics Pte. Ltd. (NYB) has received a notice of effectiveness from the SEC for its Form F-4 registration statement, the filing used for the previously announced business combination that would take NYB public on Nasdaq under the reserved ticker "NYB."
An effective registration statement means the SEC has completed its review and the deal documents can be sent to shareholders for a vote. It is not an approval of the transaction or an endorsement of the valuation.
According to the announcement, the combination assigns NYB a pre-transaction valuation of approximately US$1.5 billion. That figure is negotiated between the parties rather than set by a market, and pre-money valuations in blank-check mergers are frequently revised or not sustained after trading begins.
The9 holds its stake through its wholly owned subsidiary Gamenow.net (Hong Kong) Limited. Based on the prospectus included in the registration statement, the company said Gamenow is expected to own 15% to 16% of the combined company once the transaction closes. The range, rather than a single number, is typical for SPAC deals, where the final split depends on how many of the acquisition vehicle's shareholders redeem their shares for cash instead of rolling into the merged company.
Two conditions remain outstanding. The listing depends on the outcome of the SPAC's extraordinary general meeting scheduled for August 19, 2026 and on approval from Nasdaq. The release does not name the special purpose acquisition company involved, and does not disclose the size of its trust account, the level of redemptions to date, or whether any concurrent private placement is attached to the deal.
What NYB says it does
NYB describes itself as a Singapore-headquartered, AI-first drug discovery company working on natural compounds. The company says its platform is built around a library cataloguing more than one million natural compounds and a model called DTIGN, a drug-target interaction graph neural network, which predicts how those compounds bind to disease-related protein targets. The release describes the predictive model as fully operational and says the library and model underpin a platform branded Vecura, aimed at finding bioactive candidates that synthetic-chemistry-first approaches have not covered.
These are the company's own characterisations. The announcement contains no information on drug candidates in preclinical or clinical development, no partnership revenue, and no research and development spending.
On the commercial side, the release points to a memorandum of understanding signed in August 2025 with NVIDIA, Hewlett Packard Enterprise and Equinix, covering work on a natural compound library, scalable AI drug discovery platforms and healthcare data infrastructure. A memorandum of understanding is a statement of intent and generally not binding, and no dollar value or committed spending was attached to the arrangement. NYB also joined the Ignition AI Accelerator run with NVIDIA and Tribe in September 2024 and keeps a presence at Johnson & Johnson Innovation's JLABS, an incubator that provides lab space to early-stage life science companies.
What the release leaves out
For The9 shareholders, the material numbers are absent. The announcement gives no revenue, cash position or burn rate for NYB, no carrying value for The9's existing stake, and no indication of how much capital NYB would receive at closing after redemptions and transaction costs. Nor does it state any lock-up terms that would apply to Gamenow's holding, which determines whether the stake can be monetised soon after listing.
The9 itself is Nasdaq-listed under NCTY and has been since 2004. It describes its main current focus as the9bit, an AI game creation platform tied to a token it calls $9BIT, with the NYB equity stake presented as a separate line of exposure to AI-driven drug discovery.
Source: PR Newswire
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.